Is Ginkgo Bioworks Holdings, Inc. (DNA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 109.3% / 30% | 105.0% / 30% | 6.0% / 30% | 13.29% / 5% | ✗ NOT HALAL |
| DJIM | 109.3% / 33% | 105.0% / 33% | 6.0% / 33% | 13.29% / 5% | ✗ NOT HALAL |
| MSCI | 39.3% / 33% | 37.7% / 33% | 2.2% / 33% | 13.29% / 5% | ✗ NOT HALAL |
| S&P | 109.3% / 33% | 105.0% / 33% | 6.0% / 33% | 13.29% / 5% | ✗ NOT HALAL |
| FTSE | 39.3% / 33% | 37.7% / 33% | 2.2% / 50% | 13.29% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 72.4% | |
| Operating Margin | -209.7% | |
| Net Margin | -183.8% | |
| Return on Equity (ROE) | -51.1% | |
| Return on Assets (ROA) | -15.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$171M |
| Free Cash Flow | -$179M |
| Total Debt | $440M |
| Debt-to-Equity | 86.5 |
| Current Ratio | 4.9 |
| Total Assets | $1.1B |
Price & Trading
| Last Close | $6.41 |
| 50-Day MA | $8.24 |
| 200-Day MA | $10.36 |
| Avg Volume | 1.1M |
| Beta | 1.6 |
|
52-Week Range
$5.00
| |
About Ginkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Ginkgo Bioworks Holdings, Inc. (DNA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Ginkgo Bioworks Holdings, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Ginkgo Bioworks Holdings, Inc.'s debt ratio?
Ginkgo Bioworks Holdings, Inc.'s debt ratio is 109.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 39.3%.
What are Ginkgo Bioworks Holdings, Inc.'s key financial metrics?
Ginkgo Bioworks Holdings, Inc. has a market capitalization of $367M, and revenue of $170M. The company maintains a gross margin of 72.4% and a net margin of -183.8%. Return on equity stands at -51.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.